OBJECTIVES: Fetuin-A is an abundant plasma protein known to predict vascular disease. Fetuin-A levels are lower in patients with Alzheimer's disease in proportion to the severity of cognitive impairment, but their association with normal cognitive ageing is unknown. We evaluated the association of serum fetuin-A levels with cognitive function in community-dwelling older adults. DESIGN/PATIENTS/MEASUREMENTS: A population-based study of 1382 older adults (median age 75) who had plasma fetuin-A levels and cognitive function evaluated in 1992-1996; 855 had repeat cognitive function assessment a median of 4 years later. RESULTS: Adjusting for age, sex, education and depression, higher levels of fetuin-A were associated with better baseline performance on the Mini-Mental Status Exam (MMSE; P = 0·012) and a tendency for better Trails Making B scores (P = 0·066). In longitudinal analyses, the likelihood of a major decline (highest decile of change) in Trails B was 29% lower (P = 0·010) for each SD higher baseline fetuin-A level; odds of major decline in MMSE was 42% lower (P = 0·005) per SD higher fetuin-A for individuals with no known CVD, but were not related to fetuin-A in those with CVD (P = 0·33). Fetuin-A was not related to Category Fluency performance. Results were independent of multiple vascular risk factors and comorbid conditions. CONCLUSIONS: Higher plasma fetuin-A concentrations are associated with better performance on tests of global cognitive function and executive function and with less likelihood of major decline in these cognitive abilities over a 4-year period. Fetuin-A may serve as a biological link between vascular disease and normal age-related cognitive decline.
OBJECTIVES:Fetuin-A is an abundant plasma protein known to predict vascular disease. Fetuin-A levels are lower in patients with Alzheimer's disease in proportion to the severity of cognitive impairment, but their association with normal cognitive ageing is unknown. We evaluated the association of serum fetuin-A levels with cognitive function in community-dwelling older adults. DESIGN/PATIENTS/MEASUREMENTS: A population-based study of 1382 older adults (median age 75) who had plasma fetuin-A levels and cognitive function evaluated in 1992-1996; 855 had repeat cognitive function assessment a median of 4 years later. RESULTS: Adjusting for age, sex, education and depression, higher levels of fetuin-A were associated with better baseline performance on the Mini-Mental Status Exam (MMSE; P = 0·012) and a tendency for better Trails Making B scores (P = 0·066). In longitudinal analyses, the likelihood of a major decline (highest decile of change) in Trails B was 29% lower (P = 0·010) for each SD higher baseline fetuin-A level; odds of major decline in MMSE was 42% lower (P = 0·005) per SD higher fetuin-A for individuals with no known CVD, but were not related to fetuin-A in those with CVD (P = 0·33). Fetuin-A was not related to Category Fluency performance. Results were independent of multiple vascular risk factors and comorbid conditions. CONCLUSIONS: Higher plasma fetuin-A concentrations are associated with better performance on tests of global cognitive function and executive function and with less likelihood of major decline in these cognitive abilities over a 4-year period. Fetuin-A may serve as a biological link between vascular disease and normal age-related cognitive decline.
Authors: Penelope K Elias; Merrill F Elias; Ralph B D'Agostino; Lisa M Sullivan; Philip A Wolf Journal: Psychosom Med Date: 2005 Jan-Feb Impact factor: 4.312
Authors: Joachim H Ix; Christina L Wassel; Alka M Kanaya; Eric Vittinghoff; Karen C Johnson; Annemarie Koster; Jane A Cauley; Tamara B Harris; Steven R Cummings; Michael G Shlipak Journal: JAMA Date: 2008-07-09 Impact factor: 56.272
Authors: Anita M Hennige; Harald Staiger; Corinna Wicke; Fausto Machicao; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan Journal: PLoS One Date: 2008-03-12 Impact factor: 3.240
Authors: Emilie T Reas; Gail A Laughlin; Jaclyn Bergstrom; Donna Kritz-Silverstein; Elizabeth Barrett-Connor; Linda K McEvoy Journal: Am J Geriatr Psychiatry Date: 2017-03-16 Impact factor: 4.105
Authors: Danielle S Powell; Esther S Oh; Nicholas S Reed; Frank R Lin; Jennifer A Deal Journal: Front Aging Neurosci Date: 2022-02-28 Impact factor: 5.702
Authors: Laila Yousif Al-Ayadhi; Farah Ali Alghamdi; Lamees Abdula Altamimi; Luluh Yousef Alsughayer; Abdulrahman Mohammed Alhowikan; Dost Muhammad Halepoto Journal: Pak J Med Sci Date: 2021 Jul-Aug Impact factor: 1.088